Compliance Blog
The Critical Need to Integrate Effective Compliance Controls in the Ongoing Opioid Settlements
The current U.S. opioid epidemic has been branded as “the worst drug crisis in America’s history” and a “man-made plague.” According to the Centers for Disease Control and Prevention (“CDC”), the...
Pharmaceutical & Medical Device Compliance Congress Turns 20
It is hard to believe that this is the 20th Anniversary of the Pharma Compliance Congress. Since the Pharmaceutical Compliance Forum (“PCF”) sponsored the first Congress in 2000, the profession has...
Latest Issue of the Policy & Medicine Compliance Update
For August, our focus is once again on compliance in research, and we start with a look at the world of collaborative research. Maureen Lloyd and her fellow co-authors take an in-depth look at the...
The Time for Effective Compliance Is NOW
Recently, the Justice Department targeted three companies in the pharmaceutical and medical device industry (Rochester Drug Co-Operative, Indivior, and Life Spine) as it aims to stamp out health...
Mitchell Hamline Team Takes 2nd Place in Annual Health Law Regulatory and Compliance Competition
I am thrilled to share some great news! The 8th Annual Health Law Regulatory and Compliance Competition was held this past weekend at The University of Maryland Francis King Carey School of Law....
December 2018 Issue Now Available
Given that this is our last issue of 2018, we decided to focus on several important topics that never seem to get enough airtime. Therefore, we are featuring articles on privacy, including the...
Season’s Greetings from Whitelaw Compliance Group
Click to view larger version
Whitelaw Compliance Group Presents at the 19th Annual Pharmaceutical & Medical Device Conference
On Thursday, November 8th, Dr. Seth Whitelaw will be joining a distinguished panel of experts for an interactive discussion on the evolution of the compliance office from “Compliance 1.0 to 3.0”. ...
Open Payments 2.0 – Big Changes Are Forecast
The forecast for transparency just turned cloudy. Key Messages Tucked into the latest opioid law are changes to the Sunshine Act.Beginning in 2022, drug and device companies now must report...